Clinical trials: Rheumatoid
Rheumatoid Arthritis
A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis
To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.
- Trial name
- NCT00870467
- Testing
- Double-blind adalimumab, Open-label Adalimumab, Open-labelAdalimumabRescue
- Where
- 88 sites in Japan
- Volunteers
- 334 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems.
- Trial name
- NCT01299961
- Testing
- abatacept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Knee Pain, Chronic Osteoarthritis
ROSA Robot Used in Total Knee Replacement Post Market Study
This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of workflow efficiency, patient pain and function, and adverse event data.
- Conditions
- Knee Pain, Chronic Osteoarthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus or Flexion Deformities
- Trial name
- NCT03969654
- Testing
- PERSONA Total Knee, Vanguard Total Knee, NexGen Total Knee
- Where
- 5 sites in United States
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Zimmer Biomet
Rheumatoid Arthritis
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
This open-label, single arm study will assess the effect of RoActemra/Actemra (tocilizumab) on neutrophils and monitor safety and benefit-risk of RoActemra/Actemra treatment in patients with active rheumatoid arthritis who have…
- Trial name
- NCT01195272
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Influenza
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched control subjects .
- Trial name
- NCT01436370
- Testing
- Trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
Rheumatoid Arthritis Memory B Cells and Abatacept
Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
- Trial name
- RAMBA (NCT03652961)
- Testing
- Abatacept, DMARDs
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Osteoarthritis, Arthritis, Rheumatoid
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis…
- Trial name
- CONDOR (NCT00141102)
- Testing
- Celecoxib, Diclofenac + Omeprazole
- Where
- 194 sites in Belgium, Brazil and 30 more
- Volunteers
- 4,484 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Rheumatoid Arthritis
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
This is a Phase III, open-label study of a total of approximately 560 subjects with active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs).
- Trial name
- SUNDIAL (NCT00443651)
- Testing
- Rituximab, Anti-inflammatory drugs
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.
- Trial name
- NCT01147341
- Testing
- Cimzia
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Michael Schiff, MD
Rheumatoid Arthritis
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrexate.
- Trial name
- NCT02281552
- Testing
- Tofacitinib
- Where
- 36 sites in Japan
- Volunteers
- 209 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
The primary objective of this study is to evaluate the efficacy of 3 subcutaneous doses of mavrilimumab compared with placebo in combination with methotrexate (MTX) in subjects with moderate-to-severe adult onset Rheumatoid…
- Trial name
- NCT01706926
- Testing
- Mavrilimumab 30 mg, Mavrilimumab 100 mg, Mavrilimumab 150 mg
- Where
- 42 sites in Argentina, Bulgaria and 12 more
- Volunteers
- 420 people
- Sponsor
- MedImmune LLC
Rheumatoid Arthritis
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01855789
- Testing
- Tocilizumab (TCZ), Methotrexate (MTX)
- Where
- 155 sites in United States
- Volunteers
- 718 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Rheumatoid Arthritis
Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study
This is an observational study of composite indices, including the CLARA (CLinical ARthritis Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy in order to evaluate clinical remission and…
- Trial name
- New Indices (NCT00793403)
- Testing
- As per routinary clinical care
- Where
- Italy
- Volunteers
- 293 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid, Crohn Disease
Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
The investigators hypothesize that the anabolic effects of Genotropin (somatropin) will improve the height and weight of children with inflammatory based chronic illness who have failed to grow despite receiving adequate…
- Trial name
- NCT00511329
- Testing
- somatropin [rDNA origin] for injection
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nationwide Children's Hospital
Rheumatoid Arthritis
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.
- Trial name
- NCT00160641
- Testing
- Certolizumab Pegol
- Where
- 67 sites in United States, Bulgaria and 11 more
- Volunteers
- 567 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
The objectives of Period 1 were the following: To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly…
- Trial name
- SELECT-EARLY (NCT02706873)
- Testing
- Methotrexate, Upadacitinib
- Where
- 290 sites in United States, Argentina and 43 more
- Volunteers
- 1,002 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
N-3 PUFA and Rheumatoid Arthritis in Korea
The purpose of this study is to see if supplementation of n-3 polyunsaturated fatty acid (PUFA) can be beneficial for the patients with rheumatoid arthritis.
- Trial name
- NCT01618019
- Testing
- Omega-3 fatty acid
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Hanyang University
Rheumatoid Arthritis, Psoriatic Arthritis
Centocor Microarray Study of Patients
Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs. Specific Aim 2.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease
- Trial name
- NCT00462072
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Arthritis, Rheumatoid
Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Open-label immunogenicity, safety and efficacy study of etanercept manufactured using the high capacity process. Descriptive results will be provided however a formal hypothesis will not be tested in this trial.
- Trial name
- NCT02378506
- Testing
- etanercept
- Where
- 31 sites in Bulgaria, Croatia and 7 more
- Volunteers
- 188 people
- Sponsor
- Pfizer